Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Danion, J.-M. Articles by the Amisulpride Study Group Search for Related Content PubMed Citation Articles by Danion, J.-M. Articles by the Amisulpride Study Group, Schizophrenia Spectrum Disorders Other Neuroleptics

Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride

OBJECTIVE: The goal of this placebo-controlled study was to evaluate the efficacy and safety of low doses of amisulpride, an atypical antipsychotic of the benzamide class with high affinity for D₂ and D₃ dopamine receptors, in the treatment of schizophrenic patients with predominantly primary negative symptoms. METHOD: After completion of a 4-week washout period, schizophrenic patients with primary negative symptoms participated in a 12-week, multicenter double-blind trial of placebo (N=83), amisulpride, 50 mg/day (N=84), or amisulpride, 100 mg/day (N=75). They were evaluated with the Scale for the Assessment of Negative Symptoms, the Scale for the Assessment of Positive Symptoms, the Brief Psychiatric Rating Scale, and the Montgomery-Åsberg Depression Rating Scale. RESULTS: Both amisulpride treatment groups showed significantly greater improvement in negative symptoms than the placebo group. Positive symptom scores were low at baseline and changed minimally during the study, suggesting that the improvement in negative symptoms was independent of improvement in positive symptoms. The safety of amisulpride was comparable to that of placebo, and extrapyramidal symptoms were infrequent. Comparable efficacy and safety results were observed with either dose of amisulpride. CONCLUSIONS: These findings confirm and extend those of earlier placebo-controlled studies of low-dose amisulpride in the treatment of patients with predominantly negative symptoms of schizophrenia.

This article has been cited by other articles:

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, July 1, 2009; 35(4): 775 - 788. [Abstract] [Full Text] [PDF]

				J. Rabinowitz and O. Davidov A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications Schizophr Bull, November 1, 2008; 34(6): 1145 - 1150. [Abstract] [Full Text] [PDF]

				S. Leucht, S. Heres, J. Hamann, and J. M. Kane Methodological Issues in Current Antipsychotic Drug Trials Schizophr Bull, March 1, 2008; 34(2): 275 - 285. [Abstract] [Full Text] [PDF]

				R. W. Buchanan Persistent Negative Symptoms in Schizophrenia: An Overview Schizophr Bull, July 1, 2007; 33(4): 1013 - 1022. [Abstract] [Full Text] [PDF]

				S. Burton Symptom domains of schizophrenia: the role of atypical antipsychotic agents J Psychopharmacol, November 1, 2006; 20(6_suppl): 6 - 19. [Abstract] [PDF]

				H. A. Nasrallah and R. Lasser Improving patient outcomes in schizophrenia: achieving remission J Psychopharmacol, November 1, 2006; 20(6_suppl): 57 - 61. [Abstract] [PDF]

				S. Leucht, G. Pitschel-Walz, R. R. Engel, and W. Kissling Amisulpride, an Unusual ""Atypical"" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials Am J Psychiatry, February 1, 2002; 159(2): 180 - 190. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us